top of page
Technology for Accurate Care
 |  |  |
|---|
Technology
KAPS Biotech's studies have shown that the known drawbacks of the currently available PSA test can be overcome by our panel of biomarkers. We have shown this panel of biomarkers can (better than PSA alone) differentiate benign prostate and PCa with greater specificity and identify men who have high risk (aggressive) PCa.
Validation
The development of biomarker passes through 5 phases
-
Preclinical exploratory studies
-
Clinical assay and validation
-
Retrospective longitudinal studies
-
Prospective screening studies
-
Randomized control trials
bottom of page